Ocuphire Pharma Results

Ocuphire Pharma Nasdaq: OCUP Upcoming Catalysts in 4Q22: • Topline Results APX3330 ZETA-1 P2b trial for DR/DME NDA Filing for Nyxol for RM ● P = Presbyopia RM = Reversal of Mydriasis NVD = Night Vision Disturbances DR/DME = Diabetic Retinopathy/Diabetic Macular Edema Ocuphire PHARMA Founded in 2018, Acquired 2 Lead Assets for Front & Back of Eye Therapies with Novel MOAS & Patent Coverage to 2034+ Nyxol eyedrops ● ● ● ● ● APX3330 oral tablets Diabetic retinopathy ("DR") - diabetes-related retinal (eye) disease Reversal of Mydriasis ("RM") - eye dilation Presbyopia - age-related blurry near vision Night Vision Disturbance ("NVD") - halos, glares, starbursts Four Large Markets (~$20B US total) w/Unmet Needs and Limited to No Competition Successful Execution of 5 Trials in last 2 Years with 6 Positive Phase 3 & Phase 2 Data Read-outs for Nyxol in RM, Presbyopia, and NVD Potential 2023 commercialization opportunities in RM Near-term initiation planned for Presbyopia VEGA Phase 3 program with Nyxol alone and Nyxol with 0.4% Low Dose Pilocarpine as adjunctive therapy ● ● CO 6

View entire presentation